Screener
Sarepta Therapeutics, Inc. SRPT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208893
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Repayments of borrowings under the Revolving Credit Facility | (250,000) | — |
| Payments related to obtaining the Revolving Credit Facility | — | (3,210) |
| Net cash provided by financing activities | 241 | 12,471 |
| Decrease in cash, cash equivalents and restricted cash | (336,832) | (862,143) |
| Cash, cash equivalents and restricted cash: | ||
| Beginning of period | 814,407 | 1,118,589 |
| End of period | $477,575 | $256,446 |
| Reconciliation of cash, cash equivalents and restricted cash: |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s net change in cash?
- Sarepta Therapeutics, Inc. (SRPT) reported net change in cash of -$336.83M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s net change in cash changed year-over-year?
- Sarepta Therapeutics, Inc.'s net change in cash increased by 60.9% year-over-year, from -$862.14M to -$336.83M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Sarepta Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude